Condition
Multi-Drug Resistant Nephrotic Syndrome
Total Trials
6
Recruiting
6
Active
6
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
6Total
Early P 1 (2)
P 1 (4)
Trial Status
Recruiting6
Clinical Trials (6)
Showing 6 of 6 trials
NCT07507201Early Phase 1Recruiting
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
NCT07305116Phase 1Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
NCT06792799Early Phase 1Recruiting
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
NCT06553898Phase 1RecruitingPrimary
Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS
NCT06607991Phase 1Recruiting
Blinatumomab for CNI-Resistant/Intolerant SRNS in Children
NCT06842589Phase 1RecruitingPrimary
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS
Showing all 6 trials